All In Biotech

Drug Trial Radar · NCT03047954

Broncho-Vaxom (OM 85 BV) in Children Suffering From Atopic Dermatitis

Multicentre, Randomised, Double Blind, Placebo-controlled Study of the Efficacy and Safety of Broncho-Vaxom (OM 85 BV) in Children Suffering From Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Feb 9, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 179 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

179

Actual

Start

Jul 2003

Primary completion

Dec 2006

Study completion Dec 2006

Sponsor

Lead sponsor
Vifor PharmaIndustry
Sponsor type
Industry
First posted
Feb 9, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 6 months, up to 7 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this pilot double-blind study was to evaluate the efficacy and the safety of Broncho-Vaxom 1 capsule (3.5 mg) per day for 9 months compared to placebo on the evolution of the disease in children suffering from Atopic Dermatitis (AD).

Conditions

  • Atopic Dermatitis

Interventions

  • Broncho-VaxomDrug

    BV is an orally administered immunostimulating preparation, which consists of a lyophilised bacterial extract prepared from 8 bacterial species (Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae and ozaenae, Staphylococcus aureus, Streptococcus pyogenes and viridans, Neisseria catarrhalis)

  • Placebo - CapDrug

    Matching Placebo capsule administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Atopic Dermatitis (AD) flares over 9 months of treatmentTime frame: 9 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.